Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Affiliations

• ¹ Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic. Zackova.daniela@fnbrno.cz.
• ² Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
• ³ Dpt. of Hemato-oncology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic.
• ⁴ Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
• ⁵ Dpt. of Hemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic.
• ⁶ 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic.
• ⁷ Dpt. of Hemato-oncology, University Hospital Plzeň and Charles University, Plzeň, Czech Republic.
• ⁸ 1st Dpt. of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic.
• ⁹ Dpt. Of Hematology, University Hospital Královské Vinohrady and Charles University, Prague, Czech Republic.
• ¹⁰ Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
• ¹¹ Central European Institute of Technology (CEITEC) Masaryk University, Brno, Czech Republic.